Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.64 -0.22 (-0.82%)

Delayed Quote Updated: 2:03 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money. ↗

June 20, 2023

One of these stocks has already doubled this year.

Via The Motley Fool

If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position ↗

June 20, 2023

All three healthcare stocks have soared this year, but their share prices may not be sustainable.

Via The Motley Fool

Could Viking Therapeutics Stock Help You Become a Millionaire? ↗

June 17, 2023

Should you buy into the hype?

Via The Motley Fool

Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics? ↗

June 13, 2023

Which of these red-hot biotech stocks is the better buy right now?

Via The Motley Fool

Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years ↗

June 12, 2023

If you can tolerate the risk and have some patience, both stocks could blossom.

Via The Motley Fool

This Red-Hot Growth Stock Has Soared 885% in Just 12 Months ↗

June 08, 2023

Is it too late to buy shares of Viking Therapeutics?

Via The Motley Fool

Why Viking Therapeutics Stock Is Heating Up Today ↗

May 31, 2023

Positive analyst coverage is fueling another uptick in the biotech's stock today.

Via The Motley Fool

Viking Therapeutics Inc. (NASDAQ: VKTX) is a Stock Spotlight on 5/23

May 23, 2023

Via Investor Brand Network

Why Viking Therapeutics Stock Is Buckling Today ↗

May 18, 2023

The biotech's shares can't escape the broader downward trend among its peer group today.

Via The Motley Fool

2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street ↗

May 30, 2023

Recent moves to the upside could be the beginning of a much larger bull run.

Via The Motley Fool

3 Biotech Stocks Sitting on Huge-Upside Catalysts ↗

May 26, 2023

The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks.

Via InvestorPlace

The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes ↗

May 23, 2023

Pfizer stock surged on its diabetes news this week, but one analyst says there's a key piece missing from the story.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

May 22, 2023

Via Benzinga

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss ↗

May 22, 2023

Pfizer's diabetes drug led to faster weight loss than Novo Nordisk's Ozempic.

Via Investor's Business Daily

What 17 Analyst Ratings Have To Say About Viking Therapeutics ↗

May 17, 2023

Via Benzinga

Why Viking Therapeutics Stock Bolted Higher Today ↗

May 16, 2023

The biotech's midstage NASH candidate passed another key hurdle.

Via The Motley Fool

Why Viking Therapeutics Stock Wobbled Today ↗

May 09, 2023

The biotech's shares dipped along with the broader markets in early-morning trading today.

Via The Motley Fool

Why Viking Therapeutics Stock Briefly Popped Today ↗

April 27, 2023

The biotech's shares rose briefly this morning following a sizable price target revision by an investing firm.

Via The Motley Fool

Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug ↗

May 22, 2023

The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid.

Via Investor's Business Daily

Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke. ↗

May 22, 2023

These biotech companies are swinging for the fences. They may hit homers, they may strike out. But you'll definitely want to watch them.

Via InvestorPlace

7 Stocks That Wall Street Analysts Are Loving in May ↗

May 21, 2023

Though not perfect, an analyst rating can indicate where institutional investor sentiment lies; here are seven stocks that analysts love.

Via InvestorPlace

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗

May 16, 2023

Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in

Via Benzinga

Is Novo Nordisk Stock a Screaming Buy Right Now? ↗

May 16, 2023

The drugmaker's shares have crushed the broader markets over the past two years. Can it keep up this blistering momentum?

Via The Motley Fool

Expert Ratings for Viking Therapeutics ↗

April 25, 2023

Via Benzinga

Earnings Preview For Viking Therapeutics ↗

April 25, 2023

Via Benzinga

Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record High ↗

May 16, 2023

The company is working on a treatment for nonalcoholic steatohepatitis, or NASH.

Via Investor's Business Daily

Why Viking Therapeutics Stock Is Trading Higher Tuesday ↗

May 16, 2023

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company announced positive top-line results from a Phase

Via Benzinga

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗

May 01, 2023

These three biotech stocks were on the volatile side today.

Via The Motley Fool

Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water ↗

April 27, 2023

Mounjaro topped first-quarter sales expectations by more than $100 million.

Via Investor's Business Daily

Earnings Scheduled For April 26, 2023 ↗

April 26, 2023

Companies Reporting Before The Bell • Teck Resources (NYSE:TECK) is expected to report quarterly earnings at $1.36 per share on revenue of $3.11 billion.

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.